Capri Cardiovascular Conference 2.0 Il ruolo dell‘ ivabradina nella gestione terapeutica delle malattie cardiovascolari oggi LINEE GUIDA PER IL TRATTAMENTO DELLA CARDIOPATIA ISCHEMICA Andrea Macchi U.O.C. di Cardiologia, UTIC ed Emodinamica A.O. Ospedale di Circolo di Busto Arsizio (VA) Capri (Na), 28-29 Marzo 2014 HR AS A PREDICTOR OF CV DEATH, ADMISSION FOR HF, MI AND CORONARY REVASC IN PTS WITH CAD AND LVSD RESTING HEART RATE INDEPENDENT PREDICTOR OF MORTALITY IN CAD The Coronary Artery Surgery Study (CASS) registry 24. 913 CAD patients; 14.1-year follow-up Obiettivo fisiopatologico placebo arm (n=5438) Adjusted survival curves for cardiovascular mortality Adjusted survival curves for overall mortality CV death Admission for HF Cumulative survival +34% 1.0 1.0 0.9 0.9 0.8 +53% 0.8 P<0.0001 P<0.0001 0.7 0.7 0.6 0.6 0.5 Coronary revascularization Admission for MI +46% +38% 0.5 0 5 10 ≤62 15 20 5 0 Years after enrolment 63-70 71-76 77-82 10 15 20 1° studio prospettico ≥83 bpm Fox K et al, Lancet 2008 Diaz A, et al. Eur Heart J. 2005;26:967-974 o FC>70 bpm rischio CV aumentato cut-off 70 bpm anche in OMT Determinante del consumo di ossigeno miocardico 6.004 pts HEART RATE AND CORONARY PLAQUE RUPTURE Retrospective angiographic study 53 pts (out of 106) Heidland UE, Strauer BE. Circulation. 2001 o OR (95% CI) P Left ventricular mass > 270 g 4.92 (1.83-13.25) 0.02 Mean heart rate > 80 bpm 3.19 (1.15-8.85) 0.02 -Blocker use 0.32 (0.13-0.88) 0.02 Wall thickness IVS 1.68 (0.57-9.91) 0.06 Fractional pulse pressure 1.81 (0.67-4.90) 0.07 ACE inhibitors 0.51 (0.19-1.34) 0.06 Statins 0.42 (0.16-1.22) 0.06 RIDURRE FC RIDUCE SINTOMI , ISCHEMIA ED EVENTI • Heart rate is a major determinant of myocardial oxigen demand and development of ischaemia • Elevated heart rate is a risk factor of cardiovascular outcomes, independent of major conventional risk factors • Heart rate should be used in risk stratifications and to guide optimal medical therapy in patients with coronary disease or heart failure …and heart rate lowering reduce cardiac ischaemia and has a potential to improve the prognosis… Effects on total exercise duration Effects on time to 1 mm ST segment depression The increase in time to 1 mm ST-segment depression by 1.5 min indicates that the improvement in total exercise capacity is associated with a relevant anti-ischemic effect Tardif JC et al, Eur Heart J 2005 IVA vs -B Iva increases exercise capacity to a greater extent for every beat of heart rate reduction INITIATIVE Study Riduzione FC con -B associata ad inotropismo negativo e smascheramento della vasocostrizione coronarica a-adrenergica Tardif JC et al, Eur Heart J 2005 ANTI-ISCHEMIC AND ANTIANGINAL EFFICACY OF IVABRADINE VS AMLODIPINE Amlodipine 10 (n=404) better Ivabradine 7.5 (n=400) better P value P<0.001 Total exercise duration P<0.001 Time to limiting angina Time to angina onset P<0.001 Time to 1-mm ST-depression P<0.001 - 30 sec 0 +30 sec Ruzyllo W, et al. Drugs. 2007;67:393-405. Ivabradina , bloccante selettivo dei canali if, riducendo FC: • • diminuisce i marker dello stress ossidativo vascolare, migliora la funzione endoteliale e riduce la formazione della placca aterosclerotica riduce il rischio di eventi coronarici del 22% (p=0.023), il rischio di IMA fatale e non fatale del 36% (p=0.001) e le rivascolazzazioni coronariche del 30% (p=0.016) nei pazienti con FC basale > 70 bpm Druin A et al ,Br J Pharmacol 2008 Custodis F et al, Circulation 2008 Tardif JC, Br Med Bull 2009 Angina limitante IVA: nei pazienti sintomatici riduce l’incidenza di morte CV, IMA, scompenso (-24%) ed ospedalizzazione per IMA fatale e non (-42%), indipendentemente da FC basale K Fox et al, Eur Heart J 2009 Safety In pazienti con coronaropatia e ventricolo sinistro disfunzionante IVA puo’ essere somministrata in piena sicurezza anche con il beta-bloccante Fox K et al, Lancet 2008 PREVENZIONE SECONDARIA DELL’IMA Numero di pazienti da trattare per prevenire un evento per anno (NNT-1) Studio Eventi NNT-1 4S Eventi coronarici maggiori 63 pz SAVE IMA fatale e non 105 pz bloccanti Meta-analisi b post-IMA IMA non fatale 107 pz Ivabradina BEAUTIFUL IMA fatale e non 93 pz Statine ACE-I Tardif JC et al, Eur Heart J 2009 SAFETY OF IVABRADINE IN COMBINATION WITH BETA-BLOCKER Ivabradine Placebo Bradycardia Asymptomatic 3.0% 0.5% Symptomatic 1.1% 0.3% Withdrawal due to sinus bradycardia 0.9% 0% Kjekshus J et al, Am J Cardiol 1995 Pfeffer MA et al, N Engl J Med 1992 Freemantle N et al, B Med J 1999 Fox K et al, Lancet 2008 ANGINA ATTACKS, S-A NITRATE CONSUMPTION, HR 2,425 pts from 5 IVA randomized trial IVA reduced: angina attacks by 59.4%, nitrate consumption by 53.7% IVA had a good safety and tolerability profile in all the subpopulations assessed CHANGE IN HEART RATE (%) 5 -5 -15 -25 -35 -45 -55 2.330 pts PVD COPD DIABETES PREVIOUS CABG CVD PREVIOUS PCI CCS III PREVIOUS MI CCS I CCS II AGE>75 WOMEN -75 AGE>65 Tendera et al, Cardiology 2009 OVERALL PVD COPD DIABETES PREVIOUS CABG CVD PREVIOUS PCI CCS III PREVIOUS MI CCS I CCS II AGE>75 WOMEN AGE>65 -65 OVERALL 0 -2 -4 -6 -8 -10 -12 -14 -16 -18 CHANGE IN ANGINA ATTACKS (%) HEART RATE REDUCTION DURING EXERCISE-INDUCED MYOCARDIAL ISCHAEMIA AND STUNNING o IVA Saline IVA prima dell’ischemia riduce la disfunzione contrattile regionale, riduce significativamente la severita’ dello stunning miocardico durante il recupero, aumentando il tempo di perfusione diastolica e la perfusione subendocardica Tale effetto e’ abolito dal pacing Il -bloccante ha effetto su ischemia ma non sullo stunning per la sua azione inotropa negativa Monnet X et al, Eur Heart J 2004 CIRCULATION OF BLOOD IN CORONARY ARTERIES Coronary flow occurs only in diastole « An increase of 1% of diastolic time, increases blood flow by 2,6 to 6% in the subendocardium » - The difference between coronary artery pressure and LVEDP drives subendocardial perfusion HEART RATE REDUCTION AND ISCHEMIA Beta-Blockers Reduced cardiac work Increased diastolic time Ivabradine Reduced cardiac work Increased O2 supply Coronary dilation Preserved strength of contraction / relaxation Coronary blood flow Coronary blood flow Reduced O2 demand Increased diastolic time Additional benefits of ivabradine Reducing O2 demand Maximized O2 supply Better ventricular filling and stress cardiac adaptation “BEYOND HR REDUCTION” IVA vs -B CONTRATTILITA’ DA SFORZO GITTATA CARDIACA DA SFORZO DURATA DELLA DIASTOLE RILASCIAMENTO VS VASODILATAZIONE DA SFORZO FLUSSO CORONARICO DA SFORZO Simon L et al, J Pharmacol Exp Ther 1995 Colin P et al, Am J Physiol Heart Circ Physiol 2003 ADDITION OF IVABRADINE TO BISOPROLOL IMPROVES EXERCISE CAPACITY MORE THAN UP-TITRATION OF BISOPROLOL Work load on teadmill testing METs 7 р=0.004 6 5 4 Bisoprolol 5 mg Bisoprolol 5 mg + Ivabradine Bisoprolol 5 mg Bisoprolol 5 mg + Bisoprolol 5 mg Amosova et al J Am Coll Cardioal 2010 CHI TRATTIAMO ? QUANDO INIZIAMO IL TRATTAMENTO ? Non perdiamo una occasione -BLOCKERS TREATED CAD PTS IN THE REAL WORLD HEART RATE IN CAD PTS RECEIVING -BLOCKERS Cohort studies 3 NO B n. 1011 B n. 1215 N = 2.226 Vitale C et al Ann Int Med 2010 HR DECREASE (AT REST) VS OTHER HR-LOWERING AGENTS Ivabradine1 Diltiazem 0 180-240 mg bid2 200 - 300 mg od3 5 mg bid n=208 n=182 n=595 7.5 mg bid n=300 Atenolol1 50 mg od 100 mg od n=286 -5 -10 -15 (bpm) 1. Tardif JC, et al. Eur Heart J. 2005;26:2529-2539. 2. Wiegen HW, et al. J Cardiol Pharm. 1991;1b:S55-S60. 3. Pine MB. Circulation. 1982;65:17-22. THE CLINICAL EXPERIENCE OF THE ITALIAN DRUG AGENCY EFFECT OF IVABRADINE IN 14.256 PATIENTS WITH CORONARY ARTERY DISEASE Source AIFA - Italian Drug Agency – Ivabradine Registry 2011 Baseline Follow up Heart Rate 83 69 Angina/week GTN Use 3.3 1.7 0.67 0.3 Cardiac deaths 8 Discontinuation 136 Severe adverse reactions Confirmed SARs 9 0 Hazard ratio Risk reduction P value Fatal MI 0.69 31% 0.114 Fatal and nonfatal MI 0.64 36% 0.001 Fatal and nonfatal MI or unstable angina 0.78 22% 0.023 Fatal and nonfatal MI, unstable angina or revascularization 0.77 23% 0.009 Coronary revascularization 0.70 30% 0.016 Predefined end point IVABRADINE REDUCES CORONARY RISK IN Angina STABLE PATIENTS WITH CAD AND HR ≥ 70 BPM Fox K, et al. Lancet. 2008;372:807-816. DRUGS AND PCI ON OUTCOMES IN STABLE CAD Treatments Studies in patients with stable CAD Findings Dihydropyridine CCBs CAMELOT ACTION No impact on mortality or MI in CAMELOT ACTION: no reduction in CV events Nicorandil IONA Primary endpoint reduced, but no impact on mortality or non fatal MI Ranolazione MERLIN No reduction of CV in subanalysis in angina pectoris Beta-blockers Meta regression analysis CIBIS-II Evidence only in post-MI and CHF Others (nitrates, diltiazem, verapamil) No prognositic data in stable CAD patients Prevention Improved Reduced of MI survival revascularization -Blockers – – +/– +/- – – Nitrates – – – Trimetazidine + + + Ranolazine NA – – Nicorandil NA – – Ivabradine + + SHIFT Calcium antagonists Kereiakes DJ et al, J Am Coll Cardiol 2007 CLINICAL EFFECTS OF ANTIANGINAL AGENTS NA: not available, +: positive effect, -: no effect Adapted from: Guidelines on the management of stable angina pectoris. Eur Heart J. 2006;27:1341-1381. Fox K, et al. Lancet. 2008;372:807-816. PLACE FOR IVABRADINE IN NEW GUIDELINES? Clinical setting Class Level Stable CAD with angina HR > 60 I A Chronic heart failure with reduced LVEF I B EUROPEAN MEDICINE EVALUATION AGENCY INDICATION Ivabradine is indicated as first line therapy alone or in combination with beta-blockers for the treatment of patients with coronary artery disease IVABRADINE IN CAD • Diminishes myocardial oxygen demand • Increases myocardial oxygen supply • Does not impair contractility • Does not affect ventricular relaxation • Allows coronary vasodilatation and coronary blood flow Improves coronary perfusion and maintains cardiac performance better than alternative drug therapy IVA is twice as effective as a beta-blocker for the same degree of HR reduction GRAZIE PER L’ATTENZIONE amacchi@aobusto.it Gitt AK et al
© Copyright 2024 Paperzz